Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remigromig in NVAMD and BRVO
NCT07205887Phase 2Recruiting
- Sponsor
- EyeBio
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neovascular age-related macular degeneration (NVAMD) and branch retinal vein occlusion (BRVO) (8 arms), sponsored by EyeBio. Primary endpoint: Best-Corrected Visual Acuity at 12 weeks. Started Sep 2025; status: recruiting.
02
Conditions
neovascular age-related macular degeneration (NVAMD)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT07205887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205887.